Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Items 901–1,000 of 1,035
Ueda, S., Saeki, T., Takeuchi, H., Shigekawa, T., Yamane, T., Kuji, I., & Osaki, A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.122 · Cited by 99
“In the course of vascular remodelling, endothelial cells (ECs) are induced from bone marrow and are properly reconstructed into the microvasculature and reoxygenation could consequently occur (Jain, 2005).”
BackgroundPorta, S. L., Roth, L., Singhal, M., Mogler, C., Spegg, C., Schieb, B., Qu, X., Adams, R. H., Baldwin, H. S., Savant, S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94674 · Cited by 112
“Normalization is therefore generally associated with a reduction of metastasis (2).”
BackgroundImmune cells as tumor drug delivery vehicles.
Combes, F., Meyer, E., & Sanders, N. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.043 · Cited by 83
“In this regard, low-dose anti-angiogenic therapy might be more beneficial in treating solid tumors than high-dose therapies as the former allows normalization of the tumor vasculature which allow more efficient recruitment, adhesion and extravasation of T cells [48].”
BackgroundFederico, A. D., Rizzo, A., Carloni, R., Giglio, A. D., Bruno, R., Ricci, D., & Brandi, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2009455 · Cited by 105
“tumor blood vessels occurs, creating a more radiosensitive microenvironment [70].”
BackgroundLiu, S., Zhang, Y., Liu, Y., Wang, W., Gao, S., Yuan, W., Sun, Z., Liu, L., & Wang, C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02076-y · Cited by 110
“On the other hand, normalisation alleviates high IFP in the tumour, facilitating the delivery of ICBs and infiltration of effector immune cells, thus improving the efficacy of CIT [99].”
BackgroundRadiation‐Induced Immunogenic Cell Death for Cancer Radioimmunotherapy
Liu, T., Pei, P., Shen, W., Hu, L. T., & Yang, K. (2023) · Small Methods · doi:10.1002/smtd.202201401 · Cited by 120
PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis
Aljada, A., O’Connor, L., Fu, Y.-Y., & Mousa, S. A. (2008) · Angiogenesis · doi:10.1007/s10456-008-9118-0 · Cited by 104
Rationale for Combination Therapies for Choroidal Neovascularization
Spaide, R. F. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.07.025 · Cited by 112
Cao, Y., Sonveaux, P., Liu, S., Zhao, Y., Mi, J., Clary, B. M., Li, C.-Y., Kontos, C. D., & Dewhirst, M. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4056 · Cited by 99
“Vascular normalization is theorized to correct chaotic tumor blood flow, improve perfusion, and enhance tumor accessibility to antitumor drugs and oxygen (31).”
BackgroundPrinciples and Therapeutic Implications of Angiogenesis, Vasculogenesis and Arteriogenesis
Fischer, C., Schneider, M., & Carmeliet, P. (2006) · Springer eBooks · doi:10.1007/3-540-36028-x_6 · Cited by 125
“Moreover, it contributes to the pathogenesis of chronic inflammatory disorders such as psoriasis and myocardial or brain infarction, and leads to increased interstitial fluid pressure in tumours (Jain 2005).”
BackgroundApproaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98
“, have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
MethodVesicle-Mediated Control of Cell Function: The Role of Extracellular Matrix and Microenvironment
Rackov, G., Garcia‐Romero, N., Esteban-Rubio, S., Carrión-Navarro, J., Belda-Iniesta, C., & Ayuso‐Sacido, Á. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00651 · Cited by 110
Hosaka, K., Yang, Y., Seki, T., Du, Q., Xu, J., He, X., Wu, J., Zhang, Y., Morikawa, H., Nakamura, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17525-6 · Cited by 105
The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression
Gao, D., & Mittal, V. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.06.006 · Cited by 105
Molecularly targeted therapy for hepatocellular carcinoma
Tanaka, S., & Arii, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.01006.x · Cited by 104
Schildkopf, P., Ott, O. J., Frey, B., Wadepohl, M., Sauer, R., Fietkau, R., & Gaipl, U. S. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791959774 · Cited by 102
Zhang, J. C., Jiang, X., Jiang, Y., Guo, M., Zhang, S., Li, J., He, J., Liu, J., Wang, J., & Ouyang, L. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.016 · Cited by 106
Tumor angiogenesis and molecular targets for therapy
Cao, Y. (2009) · Frontiers in bioscience · doi:10.2741/3504 · Cited by 104
Moioli, E. K., Clark, P. A., Chen, M., Dennis, J. E., Erickson, H. P., Gerson, S. L., & Mao, J. J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003922 · Cited by 97
“requires an intimate supply of vascular networks [1,2].”
BackgroundVEGF in Tumor Progression and Targeted Therapy
Chekhonin, V. P., Shein, S. A., Korchagina, A. A., & Gurina, O. I. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990074 · Cited by 102
Peng, C., Huang, Y., & Zheng, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.020 · Cited by 102
“Tumor angiogenesis is triggered by the overexpression of proangiogenic factors such as VEGF over antiangiogenic factors such as sVEGFR1 and thrombospondins [86,88].”
BackgroundDual Size/Charge‐Switchable Nanocatalytic Medicine for Deep Tumor Therapy
Wu, W., Pu, Y., & Shi, J. (2021) · Advanced Science · doi:10.1002/advs.202002816 · Cited by 101
Kim, H., Shim, B. Y., Lee, S., Lee, J. Y., Lee, H. J., & Kim, I.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189795 · Cited by 117
“Normalization of tumor vascularity is the main concept in anti-angiogenic therapy [87].”
BackgroundAlleviating hypoxia to improve cancer immunotherapy
Fan, P., Zhang, N., Candi, E., Agostini, M., Piacentini, M., Bernassola, F., Bove, P., Alessandro, M., Giuseppe, N., Valentina, R., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02869-2 · Cited by 104
Blakeley, J. O. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0036-8 · Cited by 111
Segerström, L., Fuchs, D., Bäckman, U., Holmquist, K., Christofferson, R. H. B., & Azarbayjani, F. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000242494.94000.52 · Cited by 96
“Based on this hypothesis, antiangiogenic therapy, especially antibodies against VEGF-A such as bevacizumab, does not only reduce tumor angiogenesis but also normalizes the leaky tumor vessels and converts them back to a more normal status and thereby augments the delivery of chemotherapy and oxygen to the targeted can…”
BackgroundModulating the tumor microenvironment to increase radiation responsiveness
Karar, J., & Maity, A. M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.21.9988 · Cited by 107
The Ubiquitin-Proteasome System Meets Angiogenesis
Rahimi, N. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0555 · Cited by 115
“Mol Cancer Ther; 11(3) March 2012 Molecular Cancer Therapeutics 542”
BackgroundInfluentialYap, R. L., Veliceasa, D., Emmenegger, U., Kerbel, R. S., McKay, L. M., Henkin, J., & Volpert, O. V. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0621 · Cited by 97
Oxygen-Controlled Three-Dimensional Cultures to Analyze Tumor Angiogenesis
Verbridge, S. S., Choi, N. W., Zheng, Y., Brooks, D. J., Stroock, A. D., & Fischbach, C. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0670 · Cited by 96
Vascular Wall as a Reservoir for Different Types of Stem and Progenitor Cells
Ergün, S., Tilki, D., & Klein, D. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3507 · Cited by 109
“In the following decades, many factors and mechanisms governing angiogenesis were identified as summarized in numerous reviews (16, 36, 56, 58).”
Tyrakowski, C. M., & Snee, P. T. (2013) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp53502a · Cited by 100
Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery
Bouzin, C., & Féron, O. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.03.001 · Cited by 95
Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas
Mahase, S. S., Rattenni, R. N., Wesseling, P., Leenders, W. P. J., Baldotto, C. S. D. R., Jain, R., & Zagzag, D. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.010 · Cited by 112
Self-citationSchultheis, B. S., Folprecht, G., Kuhlmann, J. B., Ehrenberg, R., Hacker, U. T., Köhne, C.-H., Kornacker, M., Boix, O., Lettieri, J., Krauss, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt056 · Cited by 96
“(ii) Normalization of the tumor vasculature through antiangiogenic treatment might improve tumor perfusion and, consequently, delivery of systemic chemotherapy [20].”
BackgroundContribution of pericyte paracrine regulation of the endothelium to angiogenesis
Caporali, A., Martello, A., Miscianinov, V., Maselli, D., Vono, R., & Spinetti, G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.001 · Cited by 104
“essel normalization due to an increase of pericyte coverage (Jain, 2005).”
BackgroundTherapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 110
“In contrast to most preclinical studies, monotherapy with bevacizumab failed to increase patients’ overall survival (OS) (Jain, 2005), but in combination with chemotherapy it can extend progression free survival (PFS) and/or OS in several cancer types including metastatic colorectal cancer (mCRC) (Hurwitz et al.”
BackgroundResultPetrillo, M., Patella, F., Pesapane, F., Suter, M. B., Ierardi, A. M., Angileri, S. A., Floridi, C., Filippo, M. D., & Carrafiello, G. (2018) · Future Oncology · doi:10.2217/fon-2017-0739 · Cited by 99
de la Torre, P., Pérez-Lorenzo, M. J., Alcázar-Garrido, Á., & Flores, A. I. (2020) · Molecules · doi:10.3390/molecules25030715 · Cited by 94
“Lessons from the undesired consequences of blocking angiogenesis in tumor progression led to the hypothesis that normalization of the tumor vasculature is a better therapeutic option than its destruction [61].”
BackgroundImmunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Hirsch, L., Flippot, R., Escudier, B. J., & Albiges, L. K. (2020) · Drugs · doi:10.1007/s40265-020-01327-7 · Cited by 102
“VEGF pathway inhibitors seem to increase the numbers of tumorinfiltrating lymphocytes through normalization of vascularization [71].”
BackgroundPizzimenti, S., Toaldo, C., Pettazzoni, P., Dianzani, M. U., & Barrera, G. (2010) · Cancers · doi:10.3390/cancers2020338 · Cited by 112
“of the angiogenic program in controlling tumor growth is underlined by antiangiogenic gene therapy as a new therapeutic approach to the treatment of cancer patients [112].”
BackgroundDuda, D. G., Willett, C. G., Ancukiewicz, M., Tomaso, E., Shah, M., Czito, B. G., Bentley, R., Poleski, M., Lauwers, G. Y., Carroll, M., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0029 · Cited by 94
Self-citationDesign of Clinical Trials of Radiation Combined with Antiangiogenic Therapy
Senan, S., & Smit, E. F. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-465 · Cited by 98
Missiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 94
“…effects of these inhibitors were observed in a subset of cancer patients, antiangiogenic therapy has revealed very limited and transient beneficial effects by improving progression-free-survival and quality-of-life but not overall survival, and only in a fraction of cancer patients [11, 117, 118].”
Liver metastases from colorectal cancer: radioembolization with systemic therapy
Nicolay, N. H., Berry, D. P., & Sharma, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.165 · Cited by 97
Imaging Tumor Hypoxia to Advance Radiation Oncology
Lee, C.-T., Boss, M., & Dewhirst, M. W. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5759 · Cited by 107
“Therefore, an additional source of chronic hypoxia may be caused by a compromised perfusion of leaky microvessels (11, 109).”
Innovative Strategien für die photodynamische Therapie hypoxischer Tumore
Li, X., Kwon, N., Guo, T., Liu, Z., & Yoon, J. (2018) · Angewandte Chemie · doi:10.1002/ange.201805138 · Cited by 94
Hyperthermia: Cancer Treatment and Beyond
Bettaieb, A., Paulina, K., & Diana, A. (2013) · InTech eBooks · doi:10.5772/55795 · Cited by 93
“Blood flow and vascular permeability, which are increased by hyperthermia, are critical factors for drug uptake [112].”
BackgroundGerstner, E. R., Eichler, A. F., Plotkin, S. R., Drappatz, J., Doyle, C. L., Xu, L., Duda, D. G., Wen, P. Y., Jain, R. K., & Batchelor, T. T. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0390-7 · Cited by 96
“By normalizing tumor vasculature, anti-VEGF agents are thought to reduce tumor hypoxia and improve delivery of chemotherapeutics [3].”
Self-citationHeber, E. M., Hawthorne, M. F., Kueffer, P. J., Garabalino, M. A., Thorp, S. I., Pozzi, E. C. C., Hughes, A. M., Maitz, C. A., Jalisatgi, S. S., Nigg, D. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410865111 · Cited by 94
“Small liposomes (<100 nm) pass through aberrant tumor vessels (17) and passively accumulate by the enhanced permeability and retention effect (18, 19).”
BackgroundSchwartz, D. L., Bankson, J. A., Lemos, R., Lai, S. Y., Thittai, A. K., He, Y., Hostetter, G., Demeure, M. J., Von Hoff, D. D., & Powis, G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0768 · Cited by 94
“PX-478 acts indirectly on vessels through blockade of tumor cell HIF-1–mediated paracrine proangiogenic signaling, yielding transient downstream vascular normalization (39) and improved matching of vascular supply to metabolic demand, ultimately leading to tumor cell repopulation.”
BackgroundMaintenance Treatment with Bevacizumab Prolongs Survival in anIn vivoOvarian Cancer Model
Mabuchi, S., Terai, Y., Morishige, K., Tanabe-Kimura, A., Sasaki, H., Kanemura, M., Tsunetoh, S., Tanaka, Y., Sakata, M., Burger, R. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0243 · Cited by 107
Kudo, M. (2021) · Liver Cancer · doi:10.1159/000519749 · Cited by 99
Balar, A. V., Apolo, A. B., Ostrovnaya, I., Mironov, S., Iasonos, A. E., Trout, A., Regazzi, A. M., Garcia-Grossman, I. R., Gallagher, D. J., Milowsky, M. I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5215 · Cited by 93
WICKI, A. N., Rochlitz, C. F., Orleth, A., Ritschard, R., Albrecht, I., Herrmann, R., Christofori, G., & Mamot, C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1102 · Cited by 101
“This is in contrast with results found with other antiangiogenic modalities (30).”
ResultSingle-Cell Migration in Complex Microenvironments: Mechanics and Signaling Dynamics
Mak, M., Spill, F., Kamm, R. D., & Zaman, M. H. (2016) · Journal of Biomechanical Engineering · doi:10.1115/1.4032188 · Cited by 118
“Flow is a common feature in many physiological environments, from blood and lymphatic vessels to interstitial matrices and leaky tumor vasculatures [117].”
BackgroundResistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
Montemagno, C., & Pagès, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00584 · Cited by 104
“Although anti-angiogenic therapies reduce and normalize tumor vasculature, limiting tumor hypoxia, alternative theory defends an increased intra-tumor hypoxia (Kerbel and Folkman, 2002; Jain, 2005).”
BackgroundTrial Watch: Oncolytic viruses for cancer therapy
Pol, J., Bloy, N., Obrist, F., Eggermont, A., Galon, J., Cremer, I., Erbs, P., Limacher, J.-M., Preville, X., Zitvogel, L., et al. (2014) · OncoImmunology · doi:10.4161/onci.28694 · Cited by 93
“This approach may exert a dual benefit in that the inhibition of cancerassociated angiogenesis not only mediates direct antineoplastic effects,(155,156) but also causes a normalization of the tumor vasculature that improves the delivery/penetration of therapeutic agents, including oncolytic viruses themselves.(157-159…”
BackgroundChemotherapy in metastatic renal cell carcinoma today? A systematic review
Buti, S., Bersanelli, M., Sikokis, A., Maines, F., Facchinetti, F., Bria, E., Ardizzoni, A., Tortora, G., & Massari, F. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283609ec1 · Cited by 93
Minicells: Versatile vectors for targeted drug or si/shRNA cancer therapy
MacDiarmid, J. A., & Brahmbhatt, H. N. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.04.008 · Cited by 96
Characterization of the expression of the hypoxia‐induced genes neuritin, TXNIP and IGFBP3 in cancer
Jan, S. L., Meur, N. L., Cazes, A., Philippe, J., Cunff, M. L., Leger, J. J., Corvol, P. L., & Germain, S. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.05.011 · Cited by 97
“In this context, targeting the tumor vasculature to ‘‘normalize’’ it [5] temporarily or to eradicate it”
BackgroundHorst, A. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24340 · Cited by 92
Gilabert‐Oriol, R., Weng, A., von Mallinckrodt, B., Melzig, M. F., Fuchs, H., & Thakur, M. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140826153913 · Cited by 92
“It is in such cases that a “cocktail therapy” could be highly effective and beneficial [90].”
BackgroundGlioblastoma Therapy in the Age of Molecular Medicine
Geraldo, L. H., Garcia, C., da Fonseca, A. C. C., Dubois, L. G., Spohr, T. C. L. D. S. E., Matias, D., Magalhães, E. S. D. C., do Amaral, R. F., da Rosa, B. G., Grimaldi, I., et al. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.002 · Cited by 101
Volz, J., Mammadova‐Bach, E., Gil‐Pulido, J., Nandigama, R., Remer, K. A., Sorokin, L. M., Zernecke, A., Abrams, S. I., Ergün, S., Henke, E., et al. (2019) · Blood · doi:10.1182/blood.2018877043 · Cited by 113
Gloria, K., & Nie, S. (2005) · Materials Today · doi:10.1016/s1369-7021(05)71034-8 · Cited by 92
Computational Modeling of 3D Tumor Growth and Angiogenesis for Chemotherapy Evaluation
Tang, L., van de Ven, A. L., Guo, D., Andasari, V., Vittorio Cristini, C., Li, K. C., & Zhou, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083962 · Cited by 94
“4 Mass Transport Various vascular abnormalities including shunts and tortuous, leaky vessels cause considerable blood and interstitial fluid infusion into tumor microenvironment [45,46].”
BackgroundCancer cell glycocalyx mediates mechanotransduction and flow-regulated invasion
Qazi, H., Palomino, R., Shi, Z., Munn, L. L., & Tarbell, J. M. (2013) · Integrative Biology · doi:10.1039/c3ib40057c · Cited by 94
Trial Watch: Anticancer radioimmunotherapy
Vacchelli, E., Vitale, I., Tartour, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25595 · Cited by 91
Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms
Miletić, H., Niclou, S. P., Johansson, M., & Bjerkvig, R. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902806444 · Cited by 103
“Finally it has been shown that VEGF inhibition induces a morphological and functional normalization of the tumour vascular bed and thus decreases interstitial pressure and improves drug delivery to the tumour [104,105].”
BackgroundDifferential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model
Zhou, Q., & Gallo, J. M. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-088 · Cited by 91
Notch4 Normalization Reduces Blood Vessel Size in Arteriovenous Malformations
Murphy, P. A., Kim, T. N., Lu, G., Bollen, A. W., Schaffer, C. B., & Wang, R. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002670 · Cited by 95
“Microvessels in tumors and normal tissues regress after VEGF inhibition (22).”
BackgroundWang, Y., Ding, Y., Yao, D., Dong, H., Ji, C., Wu, J., Hu, Y., & Yuan, A. (2021) · Small · doi:10.1002/smll.202006231 · Cited by 100
Zhang, M., Herion, T., Timke, C., Han, N., Hauser, K., Weber, K. J., Peschke, P., Wirkner, U., Lahn, M., & Huber, P. E. (2011) · Neoplasia · doi:10.1593/neo.11258 · Cited by 94
“The interpretation of this process as a vascular normalization effect suggests improved physiological conditions for both radiotherapy and chemotherapy, which both depend on functional blood perfusion and/or ample oxygen supply [45].”
BackgroundRanibizumab Therapy for Neovascular Age-Related Macular Degeneration
Folk, J. C., & Stone, E. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmct1000495 · Cited by 91
Falcón, B. L., Barr, S. M., Gokhale, P. C., Chou, J., Fogarty, J., Depeille, P., Miglarese, M. R., Epstein, D. M., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3126 · Cited by 102
Nagy, J. D. (2005) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2005.2.381 · Cited by 104
Molecular Biology for the Radiation Oncologist: the 5Rs of Radiobiology meet the Hallmarks of Cancer
Harrington, K. J., Jankowska, P., & Hingorani, M. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.04.009 · Cited by 115
Combretastatin A4 Phosphate: A Novel Vascular Disrupting Agent
Nagaiah, G., & Remick, S. C. (2010) · Future Oncology · doi:10.2217/fon.10.90 · Cited by 92
“muscle for support are more vulnerable to these agents [25,26].”
BackgroundBullok, K. E., Maxwell, D., Kesarwala, A. H., Gammon, S., Prior, J. L., Snow, M., Stanley, S., & Piwnica-Worms, D. (2007) · Biochemistry · doi:10.1021/bi061959n · Cited by 91
Ghaghada, K. B., Badea, C. T., Karumbaiah, L., Fettig, N. M., Bellamkonda, R. V., Johnson, G. A., & Annapragada, A. (2010) · Academic Radiology · doi:10.1016/j.acra.2010.09.003 · Cited by 91
“The role of VEGF-A and its receptors has been extensively studied in the context of tumor blood vessel growth and vascular normalization [31].”
Pathways of chemotherapy resistance in castration-resistant prostate cancer
Mahon, K. L., Henshall, S. M., Sutherland, R. L., & Horvath, L. G. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0343 · Cited by 100
“…vasculature, delivery of oxygen and cytotoxic drugs to tumour tissue may be MTX, mitoxantrone; DTX, docetaxel; Ev, everolimus; rand, random rate; Bv, bevacizumab; E, estramustine; OS, overall survival; Su, s dose; HD, high dose; Ln, lenalidomide. www.endocrinology-journals.org improved (Jain 2005).”
Bohndiek, S. E., Sasportas, L. S., Machtaler, S., Jokerst, J. V., Hori, S. S., & Gambhir, S. S. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160002 · Cited by 94
“Our second key finding is that trebananib treatment normalizes, rather than completely prevents, mAng1 signaling in mature tumor vessels, leading to a more stable, less permeable, residual vascular architecture, as expected in a vascular normalization response (15).”
BackgroundHuang, N., Liu, Y., Fang, Y. V., Zheng, S., Wu, J., Wang, M., Zhong, W., Shi, M., Xing, M. M. Q., & Liao, W. (2020) · ACS Nano · doi:10.1021/acsnano.9b08460 · Cited by 93
Effect of Prenatal Glucocorticoids on Cerebral Vasculature of the Developing Brain
Vinukonda, G., Dummula, K., Malik, S., Hu, F., Thompson, C. I., Csiszar, A., Ungvari, Z., & Ballabh, P. (2010) · Stroke · doi:10.1161/strokeaha.110.588400 · Cited by 89
Benesch, M., Windelberg, M., Sauseng, W., Witt, V., Fleischhack, G., Lackner, H., Gadner, H., Bode, U., & Urban, C. E. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm510 · Cited by 93
“By specific binding to VEGF-A and its isoforms, this compound counteracts angiogenic effects induced by VEGF and allows for a normalization of tumor vasculature [13].”
BackgroundZhang, M., Ye, J.-J., Xia, Y., Wang, Z.-Y., Li, C.-X., Wang, X.-S., Yu, W., Song, W., Feng, J., & Zhang, X.-Z. (2019) · ACS Nano · doi:10.1021/acsnano.9b07330 · Cited by 89
Novel Aspects of the Liver Microenvironment in Hepatocellular Carcinoma Pathogenesis and Development
Tu, T., Budzinska, M. A., Maczurek, A. E., Cheng, R., Bartolomeo, A. D., Warner, F. J., McCaughan, G. W., McLennan, S. V., & Shackel, N. A. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069422 · Cited by 94
“For example, treatment with angiogenic agents may normalise existing aberrant vascularisation in the tumour and therefore to limit hypoxic regions [218].”
BackgroundYang, Q., Tian, Y., Liu, S., Zeine, R. R., Chlenski, A., Salwen, H. R., Henkin, J., & Cohn, S. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2595 · Cited by 94
“Transient ‘‘normalization’’ of tumor vasculature following treatment with other antiangiogenic agents has recently been reported (25).”
BackgroundNeuropilins in the Context of Tumor Vasculature
Niland, S., & Eble, J. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030639 · Cited by 98
“Also, in contrast to normal blood vessels, blood flow is disturbed in poorly differentiated, chaotically arranged, tortuous, and dilated tumor vessels [311].”
BackgroundThe future of peptides in cancer treatment
Kurrikoff, K., Aphkhazava, D., & Langel, Ü. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.01.008 · Cited by 89
Qian, C., Liu, C., Liu, W., Zhou, R., & Zhao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291530 · Cited by 101
“The appropriate use of drugs that induce vascular normalization can alleviate hypoxia and improve the ef fi cacy of conventional therapies (167, 168).”
BackgroundKemeny, N. E., Schwartz, L. H., Gönen, M., Yopp, A. C., Gültekin, D. H., D'Angelica, M. I., Fong, Y., Haviland, D., Gewirtz, A. N., Allen, P. J., et al. (2011) · Oncology · doi:10.1159/000324704 · Cited by 89
“In the updated results of this trial, there was a 50p partial response rate (53.8p for ICC and 25p for HCC) with a median survival of 29.5 months for the entire cohort.Targeted therapies have produced encouraging results and are now commonly used to treat various gastrointestinal malignancies. Many of these agents inh…”
BackgroundInfluentialTargeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes
Lila, A. S. A., Ishida, T., & Kiwada, H. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0110-1 · Cited by 102
Angiogenesis and Current Antiangiogenic Strategies for the Treatment of Cancer
Öklü, R., Walker, T. G., Wicky, S., & Hesketh, R. (2010) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2010.08.009 · Cited by 101
“However, another possibility is that VEGF inhibitors cause transient restructuring of the abnormal tumor vasculature, thereby reducing its permeability and improving blood flow and thus facilitating access of systemically administered drugs to tumor cells (97).”
BackgroundLiu, C., Wang, K., Chan, Q., Liu, Z., Zhang, J., He, H., Zhang, S., & Liang, C. (2016) · European Radiology · doi:10.1007/s00330-016-4241-6 · Cited by 88
“complete neovascular endothelium, which is associated with a higher permeability [33].”
A bioengineered array of 3D microvessels for vascular permeability assay
Lee, H., Kim, S., Chung, M., Kim, J. H., & Jeon, N. L. (2013) · Microvascular Research · doi:10.1016/j.mvr.2013.12.001 · Cited by 95
Coupled modelling of tumour angiogenesis, tumour growth and blood perfusion
Cai, Y., Xu, S., Wu, J., & Long, Q. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.02.017 · Cited by 90
Wang, J., Guo, F., Yu, M., Liu, L., Tan, F., Yan, R., & Li, N. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.005 · Cited by 88
“Unlike the normal blood vessels, the constitute of tumor vasculature is abnormal, resulting in the formation of physiological barriers which hinder the delivery of therapeutic drugs into tumors [57].”
BackgroundTyrosine Kinase Inhibitor-Induced Hypertension
Agarwal, M., Thareja, N., Benjamin, M., Akhondi, A., & Mitchell, G. D. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0708-8 · Cited by 97
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.